Sequent Scientific Intrinsic Value
SEQUENT • Healthcare
Current Stock Price
₹193.98
Primary Intrinsic Value
₹58.19
Market Cap
₹969.9 Cr
-20.6%
Downside
Median Value
₹154.11
Value Range
₹58 - ₹388
Assessment
Trading Above Calculated Value
Safety Margin
-25.9%
SEQUENT Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹58.19 | ₹46.55 - ₹69.83 | -70.0% | EPS: ₹2.36, Sector P/E: 22x |
| Book Value Method | asset | ₹308.00 | ₹277.20 - ₹338.80 | +58.8% | Book Value/Share: ₹154.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹387.96 | ₹349.16 - ₹426.76 | +100.0% | Revenue/Share: ₹340.80, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹387.96 | ₹349.16 - ₹426.76 | +100.0% | EBITDA: ₹224.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹154.11 | ₹123.29 - ₹184.93 | -20.6% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹58.19 | ₹52.37 - ₹64.01 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹58.19 | ₹52.37 - ₹64.01 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹192.00 | ₹172.80 - ₹211.20 | -1.0% | ROE: 10.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹90.43 | ₹81.39 - ₹99.47 | -53.4% | EPS: ₹2.36, BVPS: ₹154.00 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SEQUENT Intrinsic Value Analysis
What is the intrinsic value of SEQUENT?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sequent Scientific (SEQUENT) is ₹154.11 (median value). With the current market price of ₹193.98, this represents a -20.6% variance from our estimated fair value.
The valuation range spans from ₹58.19 to ₹387.96, indicating ₹58.19 - ₹387.96.
Is SEQUENT undervalued or overvalued?
Based on our multi-method analysis, Sequent Scientific (SEQUENT) appears to be trading above calculated value by approximately 20.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.67 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.08 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 10.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.06x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Sequent Scientific
Additional stock information and data for SEQUENT
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹83 Cr | ₹71 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹31 Cr | ₹28 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹17 Cr | ₹-16 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹31 Cr | ₹-16 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹115 Cr | ₹115 Cr | Positive Free Cash Flow | 8/10 |